5 Units Semaglutide Weight Loss: What Research Shows

Last reviewed: May 31, 2026

Last updated: May 31, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Yes, 5 units of semaglutide may support weight loss in some individuals, but efficacy depends heavily on where you are in the dose escalation protocol, your baseline metabolic rate, and individual variation in GLP-1 receptor expression. This dose represents approximately 0.15 mg (the typical starting point in most weight-loss protocols) and is not intended as a steady-state maintenance dose.

Understanding whether 5 units is sufficient for *your* weight-loss goals requires moving beyond generic dosing tables. PlexusDx uses a precision-wellness approach: genetic predispositions in peptide-signaling pathways, combined with clinical markers, can help contextualize why some individuals respond robustly at lower doses while others require titration to higher amounts.

Understanding the 5-Unit Starting Dose in Clinical Context

Five units of semaglutide (0.15 mg) is the standard initiation dose in most GLP-1 weight-loss protocols. This dose activates GLP-1 receptors in the hypothalamus and gut, promoting satiety and reducing appetite—but it is explicitly designed as a starting point, not a target maintenance dose. Clinical trials and real-world data show this dose produces modest weight loss in some patients while others experience minimal effect.

The dose-response relationship for semaglutide is not linear. A 2023 randomized trial showed average weight loss of 3–5% at 0.25 mg weekly, and 10–15% at 2.4 mg weekly, suggesting that individual threshold variation is substantial. Your provider will typically escalate the dose every 4 weeks to minimize nausea and maximize efficacy.

Dose Escalation Protocol and What to Expect at 5 Units

Most semaglutide weight-loss protocols follow a tiered escalation schedule. At 5 units (0.15 mg), you are in week 1–4 of treatment. This dose is rarely the endpoint; rather, it establishes tolerability and begins appetite-suppression effects. Weight loss at this stage is typically 2–4 pounds over four weeks, though many individuals report gastrointestinal adjustment rather than significant weight reduction.

Below is a typical 12-week escalation framework to contextualize the 5-unit starting dose within the broader treatment arc:

Week(s)	Semaglutide Dose (mg)	Dose (Units)	Expected Clinical Response
1–4	0.15	5	Tolerability assessment; mild appetite reduction; GI adaptation
5–8	0.30	10	Increased satiety; modest weight loss 3–5 lbs expected
9–12	0.50	17	Enhanced appetite suppression; cumulative weight loss 8–12 lbs possible
Weeks 13+	1.0–2.4	33–80	Steady-state efficacy; individualized titration per provider and tolerance

Genetic Predispositions That Influence 5-Unit Response

Individual variation in semaglutide response is partly rooted in genetic architecture. Variants in the GLP1R gene (e.g., rs6923761) affect receptor sensitivity and signaling efficiency. Similarly, FTO rs9939609 influences appetite regulation and metabolic rate. These predispositions do not determine outcomes but may contextualize why 5 units produces robust effects in some individuals and minimal response in others.

PlexusDx's Precision Peptide Genetic Test examines key variants in GLP1R, GIPR, FTO, and MC4R pathways—genes directly implicated in GLP-1 signaling and weight regulation. Understanding your genetic profile may help your provider anticipate whether you're a responder at lower doses or likely require higher titration to achieve meaningful weight loss.

Safety, Medical Suitability, and Dosing with Provider Guidance

Five units of semaglutide is generally well-tolerated in most individuals, but suitability depends on your medical history. Contraindications include a personal or family history of medullary thyroid cancer, multiple endocrine neoplasia type 2, or severe pancreatitis. Nausea, vomiting, and constipation are common in the first weeks; these side effects typically improve as your GI tract adapts or as your provider adjusts dosing timing.

Compounded semaglutide from licensed 503A pharmacies offers flexibility in dose customization and cost—ranging from $179–$229 monthly for most protocols. Importantly, your provider should supervise all dosing adjustments, baseline metabolic screening, and periodic reassessment. Semaglutide is not a standalone intervention; weight loss efficacy improves when combined with structured nutrition and movement habits.

How PlexusDx Supports a More Personalized Approach

PlexusDx's Precision Peptide Genetic Test may help provide context for your individual semaglutide response. Variants in GLP1R rs6923761 and FTO rs9939609 influence how efficiently your GLP-1 system suppresses appetite and regulates metabolic rate. This information, interpreted with your qualified healthcare provider, can inform whether starting at 5 units fits your metabolic profile or whether accelerated titration might be more appropriate.

The genetic test examines predispositions in peptide-signaling pathways—not exact medication response. A favorable genetic profile in GLP1R does not guarantee weight loss on 5 units; similarly, a less-optimized profile does not preclude response. Genetics represents one data point among many: age, insulin resistance, BMI, and behavioral factors all influence outcomes. The test should be interpreted as part of a comprehensive assessment, not a replacement for clinical evaluation.

By combining genetic insights with clinical markers (fasting glucose, triglycerides, C-reactive protein), you and your provider can build a more personalized treatment conversation. This may help determine whether 5 units is a reasonable starting point, whether you might benefit from oral semaglutide instead, or whether dual-peptide approaches (e.g., GLP-Squared) warrant exploration for your specific predispositions.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection starts at $229-$309/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.